GlassScriptPhysician profile
Bruce Russell
NPI 1336134188
$8,130.75
in general payments reported to CMS, 2019-2025
33 companies · $769 in 2025
The $769 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $912 · 2020: $1,305 · 2021: $1,250 · 2022: $1,384 · 2023: $1,438 · 2024: $1,072 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,233 · Education: $46.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,232.56 |
| Education | $46.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,507.69 | 2019-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $1,117.36 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $927.79 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $567.76 | 2019-2023 | |
| Glaxosmithkline, LLC. | $548.53 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $469.74 | 2019-2023 | Xarelto |
| Abbvie INC. | $444.05 | 2021-2025 | Ubrelvy, Qulipta |
| Novo Nordisk INC | $438.75 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $316.68 | 2019-2023 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $223.13 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $177.59 | 2019-2021 | |
| Allergan, INC. | $131.98 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $122.31 | 2022-2024 | Quviviq |
| Medicure Pharma INC. | $120.58 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.05 | 2019-2024 | Jardiance, Tradjenta |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $107.24 | 2019 | |
| Mylan Specialty L.P. | $96.69 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $88.75 | 2020-2023 | Seglentis, Livalo |
| Tris Pharma INC | $84.71 | 2023-2025 | Dyanavel Xr |
| Amarin Pharma, INC. | $73.72 | 2019-2021 | |
| Astellas Pharma US INC | $72.10 | 2024 | Veozah |
| Eisai INC. | $58.95 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $58.69 | 2019 | |
| Exact Sciences Corporation | $40.84 | 2023 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $39.85 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $35.63 | 2022 | |
| Arbor Pharmaceuticals, INC. | $35.14 | 2021 | |
| Phathom Pharmaceuticals, INC. | $26.13 | 2024 | Voquezna |
| Sumitomo Pharma America, INC. | $22.90 | 2025 | Gemtesa |
| Esperion Therapeutics, INC. | $19.94 | 2025 | Nexletol |
| Insulet Corporation | $13.25 | 2023 | Omnipod |
| Merck Sharp & Dohme LLC | $12.81 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Russell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.